Review

January 5, 2024


Comprehensive approach to controlling chronic hepatitis B in China
Shan Shan, Xinyan Zhao, Jidong Jia
Clin Mol Hepatol. 2024;30(2):135-143.

Original Article

December 29, 2023


Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, et al.
Clin Mol Hepatol. 2024;30(2):177-190.

Original Article

January 8, 2024


Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
Jinlin Hou, Edward Gane, Rozalina Balabanska, et al.
Clin Mol Hepatol. 2024;30(2):191-205.

Original Article

January 8, 2024


JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
Li Xie, Hui Chen, Li Zhang, et al.
Clin Mol Hepatol. 2024;30(2):206-224.

Original Article

January 24, 2024


Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, et al.
Clin Mol Hepatol. 2024;30(2):225-234.

Original Article

January 26, 2024


Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Clin Mol Hepatol. 2024;30(2):235-246.

Original Article

January 26, 2024


Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, et al.
Clin Mol Hepatol. 2024;30(2):247-262.


Review
1875
Comprehensive approach to controlling chronic hepatitis B in China
Shan Shan, Xinyan Zhao, Jidong Jia
Clin Mol Hepatol. 2024;30(2):135-143.   Published online January 5, 2024
View: 1353   Download: 122
Editorial
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(2):144-146.   Published online February 19, 2024
View: 875   Download: 33  Crossref: 1
Toward hepatitis C virus elimination using artificial intelligence
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2024;30(2):147-149.   Published online February 23, 2024
View: 884   Download: 41  Crossref: 1
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(2):150-153.   Published online February 22, 2024
View: 1255   Download: 38
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
Chen-Te Huang, Tai-Chung Tseng
Clin Mol Hepatol. 2024;30(2):154-156.   Published online February 22, 2024
View: 683   Download: 27
Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
Ji Eun Han, Hyo Jung Cho
Clin Mol Hepatol. 2024;30(2):160-163.   Published online February 28, 2024
View: 930   Download: 29
Linvencovir: Paving the way for functional cure in hepatitis B
Jiwon Yang, Jonggi Choi
Clin Mol Hepatol. 2024;30(2):164-165.   Published online March 6, 2024
View: 752   Download: 26
JCAD, a new potential therapeutic target in cholestatic liver disease
Byoung Kuk Jang
Clin Mol Hepatol. 2024;30(2):166-167.   Published online March 8, 2024
View: 805   Download: 24  Crossref: 1
1884
Steatotic liver disease: Know your enemies
Lung-Yi Mak
Clin Mol Hepatol. 2024;30(2):171-173.   Published online February 2, 2024
View: 892   Download: 44  Crossref: 1
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Carlos Jose Pirola, Silvia Sookoian
Clin Mol Hepatol. 2024;30(2):174-176.   Published online February 5, 2024
View: 994   Download: 38  Crossref: 1
Original Article
1873
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro
Clin Mol Hepatol. 2024;30(2):177-190.   Published online December 29, 2023
View: 5228   Download: 185  Crossref: 1
1876
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen
Clin Mol Hepatol. 2024;30(2):191-205.   Published online January 8, 2024
View: 1326   Download: 112  Crossref: 1
1877
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu
Clin Mol Hepatol. 2024;30(2):206-224.   Published online January 8, 2024
View: 1611   Download: 129  Crossref: 2
1879
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue
Clin Mol Hepatol. 2024;30(2):225-234.   Published online January 24, 2024
View: 1650   Download: 137  Crossref: 1
1881
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):235-246.   Published online January 26, 2024
View: 1729   Download: 176  Crossref: 3
1880
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clin Mol Hepatol. 2024;30(2):247-262.   Published online January 26, 2024
View: 1343   Download: 131  Crossref: 2
Letter to the Editor
1878
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(2):263-265.   Published online January 18, 2024
View: 1100   Download: 78
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(2):266-268.   Published online January 30, 2024
View: 828   Download: 28
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
Ming-Ying Lu, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(2):274-275.   Published online March 5, 2024
View: 1044   Download: 18
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
Clin Mol Hepatol. 2024;30(2):276-278.   Published online April 1, 2024
View: 673   Download: 14
1907
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances
Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu
Clin Mol Hepatol. 2024;30(2):279-280.   Published online March 20, 2024
View: 802   Download: 30  Crossref: 1
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
Clin Mol Hepatol. 2024;30(2):281-283.   Published online April 1, 2024
View: 681   Download: 10
In response to: Steatotic liver disease-know your enemies
Michael H. Le, Linda Henry, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):284-286.   Published online February 19, 2024
View: 685   Download: 15
1893
Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clin Mol Hepatol. 2024;30(2):287-290.   Published online February 23, 2024
View: 786   Download: 26
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”
Haeryoung Kim, Sook-Hyang Jeong
Clin Mol Hepatol. 2024;30(2):291-292.   Published online March 19, 2024
View: 810   Download: 20
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring
Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
Clin Mol Hepatol. 2024;30(2):293-296.   Published online February 19, 2024
View: 525   Download: 23
Reply to Correspondence
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
Byoung Kuk Jang
Clin Mol Hepatol. 2024;30(2):297-298.   Published online April 1, 2024
View: 652   Download: 10
Snapshot
1887
Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clin Mol Hepatol. 2024;30(2):299-302.   Published online February 19, 2024
View: 887   Download: 44

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 336
TOTAL : 1787368
Close layer

Important Notice: Article processing charge (APC) Increase

Starting from articles submitted on February 5, 2024, the APC for CMH will be increased to $1,500 (KRW2,000,000).

    [Close]